drugset / Trial / NCT03510546
Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis
RandomizedCrossoverDouble-blindTreatment
Summary
A randomized, placebo-controlled, double-blinded cross-over study evaluating and quantifying the effect of pyridostigmine on muscle strength and symptoms in Myasthenia Gravis (MG)
Timeline
- Start
- 2018-04-09
- Primary completion
- 2020-08-31
- Completion
- 2021-08-31
Publications
- Background Barnett C, Katzberg H, Nabavi M, Bril V. The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers. J Clin Neuromuscul Dis. 2012 Jun;13(4):201-5. doi: 10.1097/CND.0b013e31824619d5.
- Background Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010 May 4;74(18):1434-40. doi: 10.1212/WNL.0b013e3181dc1b1e.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyridostigmine | Small molecule | 60 mg | — |